Covigilant Research, LLC Clinical Trials Site Management Organization

Covigilant Research, LLC

Committed To Working Together

UNITY Biotechnology Announces Positive 12-Week Data from Phase 1 Clinical Trial of … – KULR-8,

At 12 weeks following treatment with study drug, UBX1325 demonstrated a favorable safety profile supporting further clinical development., At 12 weeks following treatment with study drug, UBX1325 demonstrated a favorable safety profile supporting further clinical development., Read More

Scroll to Top